| DB ID | MyCo_3540 |
| Title | Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: is there a clinical benefit? |
| Year | 2020 |
| PMID | 32896984 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | High risk haematology patients |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | Human Research Ethics approval was obtained (Reference: AU RED LNR/16/WMEAD/502 (4949). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Australia |
| Cohort | A prospective, non-interventional study of adult (aged ≥18 years) haematology patients at Westmead Hospital, Sydney, Australia from 1 March 2017 to 30 September 2018 was undertaken. Human Research Ethics approval was obtained (Reference: AU RED LNR/16/WMEAD/502 (4949). Patients at high risk for IFD were enrolled consecutively, as per the inclusion criteria. Fifty-seven study episodes encompassing 52 haematology patients at high risk of IFD were studied. The mean patient age was 52.7 years (range 23-71). |
| Cohort No. | 52 |
| Age Group | 23-71 |
| P Value | None |
| Sensitivity | 0.375 |
| Specificity | 0.677 |
| Positive Predictive Value | 0.231 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal diseases (IFDs) are life-threatening infections with overall 30-day mortality rates of approximately 40 %, rising to 50-80 % in severely immunocompromised or critically ill patients with septic shock. The most common pathogens causing IFDs in Germany are Candida spp., followed by Aspergillus spp. and Mucorales spp.. Reliable and early diagnosis of IFD is the central challenge in routine clinical practice. However, due to unspecific clinical symptoms and limited diagnostic approaches, the diagnosis of IFDs is often delayed or even missed. In fact, at least 50 % of invasive candidiasis cases remain blood culture negative, and prospective autopsy studies showed that the diagnosis of invasive aspergillosis is frequently missed in critically ill patients. Microbiological culture of sterile sites or histopathological examination are necessary for a confirmatory diagnosis of IFD. Although invasive diagnostic methods remain the gold standard, non-invasive diagnostics are of particular interest for daily routine. Currently, there are a number of serological biomarkers (e.g., Aspergillus galactomannan, Candida mannan/anti-mannan antibodies, and (1,3)-ß-D-glucan [BDG]) utilized in the diagnosis of IFDs. |
| Technique | Assay |
| Analysis Method | Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell® assay (Associates of Cape Cod, Falmouth - USA), serum GM (Platelia, Bio-Rad Laboratories, Hercules, CA, USA) assays |
| Validation Techniques used | Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
